Zydus Cadila has settled the patent litigation pertaining to cholesterol lowering drug Livalo (pitavastatin calcium) with Japan’s Kowa Company and Nissan Chemical.
“Cadila Healthcare Limited and its subsidiary Zydus Pharmaceuticals (USA) Inc have finalised an agreement with Kowa Company Ltd, Kowa Pharmaceuticals America Inc and Nissan Chemical Industries Ltd to settle all outstanding patent litigation related to Livalo (pitavastatin calcium) tablets,” said the company in a BSE filings yesterday.
Pitavastatin, a member of the blood cholesterol lowering medication class of statins, is indicated for hypercholesterolaemia (elevated cholesterol) and for the prevention of cardiovascular disease. Pitavastatin was discovered in Japan by Nissan Chemical